Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39 results about "OREXIN A RECEPTOR" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Small-molecule agonists for type-2 orexin receptor
ActiveUS8258163B2Effectively treated for narcolepsyEffective treatmentBiocideOrganic active ingredientsWhole bodyGeneral anaesthesia
Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Antianxiety drugs and a method of screening the same
InactiveUS20070160538A1Alleviate and eliminate anxietyNervous disorderPeptide/protein ingredientsAnti-Anxiety EffectOREXIN A RECEPTOR
An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of using orexin-A.
Owner:EISIA R&D MANAGEMENT CO LTD
Compositions and methods for treating insomnia
ActiveUS10188652B2Avoidance of residual sleepinessOrganic active ingredientsNervous disorderOREXIN A RECEPTOROrexin Receptor Antagonists
Owner:EISIA R&D MANAGEMENT CO LTD
Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
InactiveUS8093255B2Improve oral bioavailabilityImprove solubilityBiocideOrganic active ingredientsOREXIN A RECEPTOROrexin Receptor Antagonists
![Imidazo[1,2-A]pyrimidines as orexin receptor antagonists](https://images-eureka.patsnap.com/patent_img/bdace521-7df1-4fd7-96bf-4aa358fdea69/US08093255-20120110-C00001.png "Imidazo[1,2-A]pyrimidines as orexin receptor antagonists")
![Imidazo[1,2-A]pyrimidines as orexin receptor antagonists](https://images-eureka.patsnap.com/patent_img/bdace521-7df1-4fd7-96bf-4aa358fdea69/US08093255-20120110-C00002.png "Imidazo[1,2-A]pyrimidines as orexin receptor antagonists")
![Imidazo[1,2-A]pyrimidines as orexin receptor antagonists](https://images-eureka.patsnap.com/patent_img/bdace521-7df1-4fd7-96bf-4aa358fdea69/US08093255-20120110-C00003.png "Imidazo[1,2-A]pyrimidines as orexin receptor antagonists")
Owner:GLAXO GRP LTD
Small-molecule agonists for type-2 orexin receptor
ActiveUS8871794B2High expressionEnhanced wakefulnessOrganic active ingredientsBiocideGeneral anaesthesiaOREXIN A RECEPTOR
Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Substituted quinazoline compounds and preparation and uses thereof
ActiveUS10196383B2Good prospect in clinical applicationExcellent physical and chemical property and pharmacokinetic propertyOrganic active ingredientsNervous disorderDiseaseOREXIN A RECEPTOR
Owner:SUNSHINE LAKE PHARM CO LTD
Solid Dispersion Comprising An Orexin Receptor Antagonist
InactiveUS20170027873A1Good dispersionImprove long-term stabilityOrganic active ingredientsNervous disorderOREXIN A RECEPTOROrexin Receptor Antagonists
A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.
Owner:SANDOZ AG
Benzimidazole-proline derivatives
ActiveCN104334544AOrganic active ingredientsNervous disorderOREXIN A RECEPTOROrexin Receptor Antagonists
The present invention relates to compounds of the formula (I) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
Owner:IDORSIA PHARM LTD
Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2- yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
![Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists](https://images-eureka.patsnap.com/patent_img/c68bd4d8-0f9f-4a80-b47a-ece6cb049e02/HDA0001003418360000011.PNG "Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists")
![Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists](https://images-eureka.patsnap.com/patent_img/c68bd4d8-0f9f-4a80-b47a-ece6cb049e02/HDA0001003418360000012.PNG "Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists")
![Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists](https://images-eureka.patsnap.com/patent_img/c68bd4d8-0f9f-4a80-b47a-ece6cb049e02/HDA0001003418360000021.PNG "Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists")
Owner:IDORSIA PHARM LTD
Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof
The invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives and a use thereof. The above compounds and a medicinal composition containing the compounds are used for suppressing an orexin receptor. The invention also relates to a method for preparing the compounds and the medicinal composition, and the use of the compounds and the medicinal composition in the treatment or prevention of orexin receptor related diseases.
![Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof](https://images-eureka.patsnap.com/patent_img/32d65363-17d6-4f08-b8f5-7b6ffca9df4d/BDA0001208963250000021.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof](https://images-eureka.patsnap.com/patent_img/32d65363-17d6-4f08-b8f5-7b6ffca9df4d/BDA0001208963250000031.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof](https://images-eureka.patsnap.com/patent_img/32d65363-17d6-4f08-b8f5-7b6ffca9df4d/BDA0001208963250000041.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Octahydropyrrolo[3,4-c]pyrrole derivative and application thereof
ActiveCN109988170AGood brain/plasma ratioImprove bioavailabilityOrganic active ingredientsNervous disorderOREXIN A RECEPTORPyrrole
The invention relates to an octahydropyrrolo[3,4-c]pyrrole derivative and application thereof. The compound and a pharmaceutical composition containing the compound are used for antagonizing orexin receptors. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in treating or preventing diseases related to orexin receptors.
![Octahydropyrrolo[3,4-c]pyrrole derivative and application thereof](https://images-eureka.patsnap.com/patent_img/408a539b-50b7-4679-a313-fd8fcccc7acb/FDA0001531559240000011.png "Octahydropyrrolo[3,4-c]pyrrole derivative and application thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivative and application thereof](https://images-eureka.patsnap.com/patent_img/408a539b-50b7-4679-a313-fd8fcccc7acb/FDA0001531559240000012.png "Octahydropyrrolo[3,4-c]pyrrole derivative and application thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivative and application thereof](https://images-eureka.patsnap.com/patent_img/408a539b-50b7-4679-a313-fd8fcccc7acb/FDA0001531559240000021.png "Octahydropyrrolo[3,4-c]pyrrole derivative and application thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Octahydropyrrolo[3,4-c]pyrrole derivative and application method and application thereof
ActiveCN107759620AImprove bioavailabilityGood metabolic stabilityOrganic active ingredientsNervous disorderOREXIN A RECEPTORPyrrole derivatives
The invention relates to an octahydropyrrolo[3,4-c]pyrrole derivative and an application method and application thereof. The compound and a pharmaceutical composition containing the compound are usedfor antagonizing orexin receptors. The invention also relates to a method for preparing the compound and the pharmaceutical composition and their application in treatment or prevention of diseases related to the orexin receptors.
![Octahydropyrrolo[3,4-c]pyrrole derivative and application method and application thereof](https://images-eureka.patsnap.com/patent_img/56fece27-8f0b-4a3a-beb2-576c34ff5ccb/FDA0001079848220000011.png "Octahydropyrrolo[3,4-c]pyrrole derivative and application method and application thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivative and application method and application thereof](https://images-eureka.patsnap.com/patent_img/56fece27-8f0b-4a3a-beb2-576c34ff5ccb/FDA0001079848220000012.png "Octahydropyrrolo[3,4-c]pyrrole derivative and application method and application thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivative and application method and application thereof](https://images-eureka.patsnap.com/patent_img/56fece27-8f0b-4a3a-beb2-576c34ff5ccb/FDA0001079848220000021.png "Octahydropyrrolo[3,4-c]pyrrole derivative and application method and application thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/0076011d-bf92-4b1f-9acb-cac256e0337f/BDA0001520801380000021.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/0076011d-bf92-4b1f-9acb-cac256e0337f/BDA0001520801380000031.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/0076011d-bf92-4b1f-9acb-cac256e0337f/BDA0001520801380000041.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of the preparing the orexin receptor antagonist compound 5-3 and its crystalline forms, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.
Owner:SHANGHAI HAIYAN PHARMA TECH +1
Improved synthetic process for preparing (2H-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators
Owner:JANSSEN PHARMA NV
Substituted aryl heteroaryl compound and application thereof
ActiveCN106674207AGood effectGood brain/plasma ratioOrganic active ingredientsNervous disorderArylDisease
The invention relates to a substituted aryl heteroaryl compound and application thereof, and further relates to a pharmaceutical composition containing the substituted aryl heteroaryl compound and application thereof. The compound or the pharmaceutical composition can be used for an antagonistic orexin receptor. The invention further relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition to preparation of drugs for treating or preventing nervous and psychogenic disorders and diseases of central nervous systems of mammals, especially human beings.
Owner:SUNSHINE LAKE PHARM CO LTD
Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/1f04ca61-10d3-4572-85bb-d7b2cd903afb/HDA0002796729500000011.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/1f04ca61-10d3-4572-85bb-d7b2cd903afb/HDA0002796729500000012.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/1f04ca61-10d3-4572-85bb-d7b2cd903afb/HDA0002796729500000021.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
Owner:SUNSHINE LAKE PHARM CO LTD
Human monoclonal antibodies against orexin receptor type 1
ActiveUS10758615B2Easy to assembleIncrease and decrease stabilityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHeavy chainAntiendomysial antibodies
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof
![Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof](https://images-eureka.patsnap.com/patent_img/3d419e78-0911-4249-865a-364848ce7a33/BDA0001079848230000021.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof](https://images-eureka.patsnap.com/patent_img/3d419e78-0911-4249-865a-364848ce7a33/BDA0001079848230000022.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof](https://images-eureka.patsnap.com/patent_img/3d419e78-0911-4249-865a-364848ce7a33/BDA0001079848230000031.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/3e5bdca2-f6e9-4203-80b4-f58548453329/BDA0001531448450000021.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/3e5bdca2-f6e9-4203-80b4-f58548453329/BDA0001531448450000031.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/3e5bdca2-f6e9-4203-80b4-f58548453329/BDA0001531448450000032.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Benzimidazole Proline Derivatives
Owner:IDORSIA PHARM LTD
Crystal form of octahydropyrrolo[3,4-c]pyrrole derivative
The invention relates to a crystal form of an octahydropyrrolo[3,4-c]pyrrole derivative. The invention also relates to a pharmaceutical composition containing the crystal form, and an application of the crystal form or the pharmaceutical composition in preparation of medicines for preventing, treating or relieving diseases related to orexin receptors.
![Crystal form of octahydropyrrolo[3,4-c]pyrrole derivative](https://images-eureka.patsnap.com/patent_img/5688d7db-6825-4c68-b889-6ac1b9252142/HDA0002796729500000011.png "Crystal form of octahydropyrrolo[3,4-c]pyrrole derivative")
![Crystal form of octahydropyrrolo[3,4-c]pyrrole derivative](https://images-eureka.patsnap.com/patent_img/5688d7db-6825-4c68-b889-6ac1b9252142/HDA0002796729500000012.png "Crystal form of octahydropyrrolo[3,4-c]pyrrole derivative")
![Crystal form of octahydropyrrolo[3,4-c]pyrrole derivative](https://images-eureka.patsnap.com/patent_img/5688d7db-6825-4c68-b889-6ac1b9252142/HDA0002796729500000021.png "Crystal form of octahydropyrrolo[3,4-c]pyrrole derivative")
Owner:SUNSHINE LAKE PHARM CO LTD
Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof
The invention relates to an ctahydropyrrole[3, 4-c]pyrrole derivative and a using method and application thereof. A compound and a drug composition containing the same are used for resisting orexin receptors. The invention further relates to methods of preparing the compound and the drug composition and application of the compound and the drug composition in treating or preventing diseases related to the orexin receptors.
![Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof](https://images-eureka.patsnap.com/patent_img/5e3ba0cf-6c8e-4404-984a-6c5a16720776/BDA0000998432330000021.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof](https://images-eureka.patsnap.com/patent_img/5e3ba0cf-6c8e-4404-984a-6c5a16720776/BDA0000998432330000022.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof](https://images-eureka.patsnap.com/patent_img/5e3ba0cf-6c8e-4404-984a-6c5a16720776/BDA0000998432330000032.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and methods and uses thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/60e9b543-fea7-4fca-92a5-c0decbfe3db7/BDA0001531559250000021.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/60e9b543-fea7-4fca-92a5-c0decbfe3db7/BDA0001531559250000022.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
![Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof](https://images-eureka.patsnap.com/patent_img/60e9b543-fea7-4fca-92a5-c0decbfe3db7/BDA0001531559250000031.png "Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof")
Owner:SUNSHINE LAKE PHARM CO LTD
Improved synthetic methods of making (2h-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators
Processes for preparing (((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanoneare described, which are useful for commercial manufacturing. Said compound is an orexin receptor modulator and may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia and depression.
Owner:JANSSEN PHARMA NV
Piperidine derivatives as orexin receptor antagonists
The invention discloses a series of piperidine derivatives as orexin receptor antagonists and their compositions, and relates to their use in the preparation and treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, drowsiness, anxiety, compulsion, panic, Drug use in nicotine dependence or disordered eating disorders.
Owner:SHANGHAI HAIYAN PHARMA TECH +2
Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/7ad43c03-5cdf-45a6-9dec-a4a941d3c28b/HDA0002797030370000011.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/7ad43c03-5cdf-45a6-9dec-a4a941d3c28b/HDA0002797030370000012.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/7ad43c03-5cdf-45a6-9dec-a4a941d3c28b/HDA0002797030370000021.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
Owner:SUNSHINE LAKE PHARM CO LTD
Proline sulfonamide derivatives as orexin receptor antagonists
The present invention relates to (S)-proline sulfonamide compounds of formula (I), wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
Owner:IDORSIA PHARM LTD
Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives
The present invention relates to crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives. The present invention also relates to a pharmaceutical composition comprising the crystalline form, and the use of the crystalline form or the pharmaceutical composition in the manufacture of a medicament for preventing, treating or alleviating orexin receptor-related diseases.
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/8694032f-99f2-482c-b9e2-008a751209b8/HDA0002796966170000011.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/8694032f-99f2-482c-b9e2-008a751209b8/HDA0002796966170000012.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
![Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives](https://images-eureka.patsnap.com/patent_img/8694032f-99f2-482c-b9e2-008a751209b8/HDA0002796966170000021.png "Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives")
Owner:SUNSHINE LAKE PHARM CO LTD
Human monoclonal antibodies against orexin receptor type 1
ActiveUS20180002421A1Easy to assembleIncrease and decrease stabilityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsOrexin receptor 1Monoclonal
The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com